Mithra updates on cash position

  • Mithra’s current cash of EUR 6.5 million is expected to cover its current cash runway through early March
  • Mithra is actively engaging with stakeholders
  • Mithra will present its results for the full year 2023 on 8 March 2024


Liege, Belgium, 6 February 2024 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.

Update on cash runway

Mithra’s management team has been exploring over recent months various strategic options. This includes appointing debt advisors and various investment banks with a view to selling certain assets and raising additional equity capital.

As of today, Mithra has sufficient cash through early March.

As a result, Mithra has entered discussions with its secured lenders to extend its cash runway. Mithra will also be approaching existing and new investors and take other cash preservation measures.

Certain of Mithra’s secured lenders have written to the Company indicating that they stand ready to engage with the Company.

Mithra will present its results for the full year 2023 on 8 March 2024.

Remediation plan

To address its working capital needs, Mithra continues to work in close collaboration with its advisors and secured lenders to activate a remediation plan with a view to creating and optimizing value for all its stakeholders and extending the Company’s cash runway. Among other things, the Company is working to implement the following measures:

  • Seeking to sell or out-license various assets
  • Actively evaluating, together with its advisors, the best strategic alternatives for two of its non-core businesses: Novalon (the Company’s complex therapeutics business); and its state-of-the-art CDMO facility
  • Mithra’s management expects to enter a DONESTA® license and supply agreement(s) for the United States in 2024, which should generate upfront payments, supply revenues and royalties
  • Exploring the sale of its rights to receive future milestone and royalty payments under its existing license and collaboration agreements
  • Accelerating cost-saving initiatives, including putting some ongoing R&D on hold; actively renegotiating contracts with various active pharmaceutical ingredient suppliers; and, stopping all discretionary capital expenditures
  • DONESTA® and ESTELLE® clinical safety studies and regulatory support for MYRING® will continue
  • Mithra has delayed or put on hold R&D projects related to the use of estetrol for neurotherapy and the wound-healing
  • The Company is pursuing strategic collaborations to fund its research and development for new innovative therapeutics programs in the women’s health space
  • To support the above-mentioned measures, the Company also is exploring an equity raise with existing and/or new investors


Please read this carefully as it applies to all persons who visit this website. The following pages contain information relating to an offering and/or admission to trading on a regulated market in relation to securities of Mithra Pharmaceuticals SA ("Mithra Pharmaceuticals"). This information may not be accessed by residents of certain countries based on applicable securities law regulations. Accordingly, if you wish to access this part of the website you must first inform yourself about and then observe the statutory and regulatory requirements applicable to you and to your jurisdiction. In order to establish whether or not you may view the information and documents please read the disclaimer below in full.


This website and the information contained herein or to which it gives access are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the "United States"), Australia, Japan or South Africa, and do not constitute, or form part of, an offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, nor shall there be any sale or purchase of, any securities of Mithra Pharmaceuticals in the United States, Australia, Japan or South Africa or in any other jurisdiction in which such offer, invitation, solicitation, sale, issue, purchase or subscription would be unlawful prior to registration, unless an exemption from registration or qualification under the securities laws of any such jurisdiction is applicable. The securities of Mithra Pharmaceuticals referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act. There will be no public offering of Mithra Pharmaceuticals' securities in the United States.

All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Mithra Pharmaceuticals assumes no responsibility if there is a violation of applicable law and regulations by any person.

No action has been taken by Mithra Pharmaceuticals that would permit an offer of Mithra's securities or the possession or distribution of the materials to which this website gives access or any other offering or publicity material relating to Mithra's securities in any jurisdiction where action for that purpose is required.

Mithra Pharmaceuticals has not authorised any public offering in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area that has implemented Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended from time to time (together with any applicable implementing measures in such Member State, the "Prospectus Regulation"), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Regulation.

In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates, is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Access to electronic versions of these materials is being made available on this webpage by Mithra Pharmaceuticals in good faith and for information purposes only.

By checking the acceptance box below, you confirm and certify that: You are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction, and that you are either: (a) a resident of, and domiciled in, a Member State of the European Economic Area and a qualified investor within the meaning of the Prospectus Regulation, (b) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Regulation and a Relevant Person, or (c) otherwise authorised to access this information pursuant to applicable laws or regulations.